newsfilter
← Latest News
Business Wire·

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

  • Alkermes plc will present 11 posters at the American Society of Clinical Psychopharmacology Annual Meeting in Miami from May 26-29, 2026.
  • Presentations cover clinical & real-world data for commercial medicines LYBALVI (olanzapine & samidorphan) & ARISTADA (aripiprazole lauroxil) & the investigational orexin 2 receptor agonist portfolio including alixorexton, ALKS 4510, & ALKS 7290.
  • Highlights include findings from the ASPIRE survey on cognitive impairment & fatigue in narcolepsy types 1 & 2 & idiopathic hypersomnia.
  • Data supporting the rationale for orexin 2 receptor agonists as treatments for sleep-wake disturbances, fatigue, & cognitive deficits in neuropsychiatric diseases will be shared.
  • Real-world retrospective claims analysis evaluates LYBALVI persistence & adherence versus other oral second-generation antipsychotics in adults with schizophrenia.
  • Phase 2 Vibrance-1 study results for alixorexton in narcolepsy type 1 regarding disease severity, cognitive function, & fatigue are presented.
  • Data on ARISTADA INITIO initiation for acute schizophrenia exacerbations & subsequent outpatient safety & efficacy are included.
  • Real-world comparisons of LYBALVI vs. olanzapine assess treatment patterns & acute care events in schizophrenia or bipolar I disorder patients.
  • LYBALVI is approved for schizophrenia & bipolar I disorder but carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis.
  • LYBALVI is contraindicated in patients using opioids or undergoing acute opioid withdrawal due to risks of severe withdrawal & life-threatening overdose.
  • ARISTADA & ARISTADA INITIO are indicated for schizophrenia in adults & carry a boxed warning for increased mortality in elderly patients with dementia-related psychosis.
  • ARISTADA & ARISTADA INITIO carry warnings regarding neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, & potential for compulsive behaviors.
  • Alixorexton is an investigational oral orexin 2 receptor agonist receiving Breakthrough Therapy designation from the FDA for narcolepsy type 1.
  • Alixorexton is currently being evaluated in Phase 3 Brilliance Studies for narcolepsy types 1 & 2 & Phase 2 Vibrance-3 studies for idiopathic hypersomnia.